MedTrace Logo

Lean Body Mass and Side Effects in Patients With Lymphoma

NCT04698616 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 141

Last updated 2021-01-07

No results posted yet for this study

Summary

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

Conditions

  • Malignant Lymphoma

Sponsors & Collaborators

  • Jens Rikardt Andersen

    lead OTHER

Principal Investigators

  • Jens R Andersen, MD,MPA · University of Copenhagen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-09
Primary Completion
2021-01-31
Completion
2021-03-03

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04698616 on ClinicalTrials.gov